High-dose chemotherapy and auto-SCT in elderly patients with Hodgkin's lymphoma

N. Puig, M. Pintilie, T. Seshadri, K. Al-Farsi, N. Franke, A. Keating, J. Kuruvilla, M. Crump

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Our purpose was to assess efficacy and toxicity of high-dose chemotherapy (HDCT) and ASCT in patients with relapsed and refractory Hodgkin's lymphoma (HL) aged 60 years and older and compare the results with a group of younger HL patients treated in a similar manner. We identified 15 consecutive patients, with HL aged 60 years and older who underwent HDCT (etoposide 60 mg/kg melphalan 160 mg/m 2) and ASCT at our institution from May 2001 to March 2008. The results were compared with a cohort of 157 younger HL patients treated in a similar manner from January 1999 to December 2006. After a median follow-up of 2.5 years, PFS at 3 years after ASCT was 73% (95% confidence interval (CI) 37-90) for the older group and 56% (95% CI 46-64) for the younger group (P=0.45); OS after ASCT was 88% (95% CI 39-98) for the older group and 84% (95% CI 75-90) for the younger group (P=0.80). No transplant-related deaths were seen. Our study suggests that ASCT is feasible for selected elderly patients with HL, giving similar results to younger patients in terms of survival and toxicity.

Original languageEnglish
Pages (from-to)1339-1344
Number of pages6
JournalBone Marrow Transplantation
Volume46
Issue number10
DOIs
Publication statusPublished - Oct 2011

Fingerprint

Hodgkin Disease
Drug Therapy
Confidence Intervals
Melphalan
Etoposide
Transplants
Survival

Keywords

  • autologous
  • elderly
  • Hodgkin
  • lymphoma

ASJC Scopus subject areas

  • Hematology
  • Transplantation

Cite this

Puig, N., Pintilie, M., Seshadri, T., Al-Farsi, K., Franke, N., Keating, A., ... Crump, M. (2011). High-dose chemotherapy and auto-SCT in elderly patients with Hodgkin's lymphoma. Bone Marrow Transplantation, 46(10), 1339-1344. https://doi.org/10.1038/bmt.2010.294

High-dose chemotherapy and auto-SCT in elderly patients with Hodgkin's lymphoma. / Puig, N.; Pintilie, M.; Seshadri, T.; Al-Farsi, K.; Franke, N.; Keating, A.; Kuruvilla, J.; Crump, M.

In: Bone Marrow Transplantation, Vol. 46, No. 10, 10.2011, p. 1339-1344.

Research output: Contribution to journalArticle

Puig, N, Pintilie, M, Seshadri, T, Al-Farsi, K, Franke, N, Keating, A, Kuruvilla, J & Crump, M 2011, 'High-dose chemotherapy and auto-SCT in elderly patients with Hodgkin's lymphoma', Bone Marrow Transplantation, vol. 46, no. 10, pp. 1339-1344. https://doi.org/10.1038/bmt.2010.294
Puig, N. ; Pintilie, M. ; Seshadri, T. ; Al-Farsi, K. ; Franke, N. ; Keating, A. ; Kuruvilla, J. ; Crump, M. / High-dose chemotherapy and auto-SCT in elderly patients with Hodgkin's lymphoma. In: Bone Marrow Transplantation. 2011 ; Vol. 46, No. 10. pp. 1339-1344.
@article{e61d8fe7554a40288096537b4ba098b9,
title = "High-dose chemotherapy and auto-SCT in elderly patients with Hodgkin's lymphoma",
abstract = "Our purpose was to assess efficacy and toxicity of high-dose chemotherapy (HDCT) and ASCT in patients with relapsed and refractory Hodgkin's lymphoma (HL) aged 60 years and older and compare the results with a group of younger HL patients treated in a similar manner. We identified 15 consecutive patients, with HL aged 60 years and older who underwent HDCT (etoposide 60 mg/kg melphalan 160 mg/m 2) and ASCT at our institution from May 2001 to March 2008. The results were compared with a cohort of 157 younger HL patients treated in a similar manner from January 1999 to December 2006. After a median follow-up of 2.5 years, PFS at 3 years after ASCT was 73{\%} (95{\%} confidence interval (CI) 37-90) for the older group and 56{\%} (95{\%} CI 46-64) for the younger group (P=0.45); OS after ASCT was 88{\%} (95{\%} CI 39-98) for the older group and 84{\%} (95{\%} CI 75-90) for the younger group (P=0.80). No transplant-related deaths were seen. Our study suggests that ASCT is feasible for selected elderly patients with HL, giving similar results to younger patients in terms of survival and toxicity.",
keywords = "autologous, elderly, Hodgkin, lymphoma",
author = "N. Puig and M. Pintilie and T. Seshadri and K. Al-Farsi and N. Franke and A. Keating and J. Kuruvilla and M. Crump",
year = "2011",
month = "10",
doi = "10.1038/bmt.2010.294",
language = "English",
volume = "46",
pages = "1339--1344",
journal = "Bone Marrow Transplantation",
issn = "0268-3369",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - High-dose chemotherapy and auto-SCT in elderly patients with Hodgkin's lymphoma

AU - Puig, N.

AU - Pintilie, M.

AU - Seshadri, T.

AU - Al-Farsi, K.

AU - Franke, N.

AU - Keating, A.

AU - Kuruvilla, J.

AU - Crump, M.

PY - 2011/10

Y1 - 2011/10

N2 - Our purpose was to assess efficacy and toxicity of high-dose chemotherapy (HDCT) and ASCT in patients with relapsed and refractory Hodgkin's lymphoma (HL) aged 60 years and older and compare the results with a group of younger HL patients treated in a similar manner. We identified 15 consecutive patients, with HL aged 60 years and older who underwent HDCT (etoposide 60 mg/kg melphalan 160 mg/m 2) and ASCT at our institution from May 2001 to March 2008. The results were compared with a cohort of 157 younger HL patients treated in a similar manner from January 1999 to December 2006. After a median follow-up of 2.5 years, PFS at 3 years after ASCT was 73% (95% confidence interval (CI) 37-90) for the older group and 56% (95% CI 46-64) for the younger group (P=0.45); OS after ASCT was 88% (95% CI 39-98) for the older group and 84% (95% CI 75-90) for the younger group (P=0.80). No transplant-related deaths were seen. Our study suggests that ASCT is feasible for selected elderly patients with HL, giving similar results to younger patients in terms of survival and toxicity.

AB - Our purpose was to assess efficacy and toxicity of high-dose chemotherapy (HDCT) and ASCT in patients with relapsed and refractory Hodgkin's lymphoma (HL) aged 60 years and older and compare the results with a group of younger HL patients treated in a similar manner. We identified 15 consecutive patients, with HL aged 60 years and older who underwent HDCT (etoposide 60 mg/kg melphalan 160 mg/m 2) and ASCT at our institution from May 2001 to March 2008. The results were compared with a cohort of 157 younger HL patients treated in a similar manner from January 1999 to December 2006. After a median follow-up of 2.5 years, PFS at 3 years after ASCT was 73% (95% confidence interval (CI) 37-90) for the older group and 56% (95% CI 46-64) for the younger group (P=0.45); OS after ASCT was 88% (95% CI 39-98) for the older group and 84% (95% CI 75-90) for the younger group (P=0.80). No transplant-related deaths were seen. Our study suggests that ASCT is feasible for selected elderly patients with HL, giving similar results to younger patients in terms of survival and toxicity.

KW - autologous

KW - elderly

KW - Hodgkin

KW - lymphoma

UR - http://www.scopus.com/inward/record.url?scp=80053972813&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053972813&partnerID=8YFLogxK

U2 - 10.1038/bmt.2010.294

DO - 10.1038/bmt.2010.294

M3 - Article

C2 - 21243027

AN - SCOPUS:80053972813

VL - 46

SP - 1339

EP - 1344

JO - Bone Marrow Transplantation

JF - Bone Marrow Transplantation

SN - 0268-3369

IS - 10

ER -